2024 Bio Asia Taiwan | It was our pleasure to meet you at our booth and seminar

Bio Asia-Taiwan 2024 | Thank you for visiting our booth and seminar

We want to extend a warm thank you to everyone who visited us at Bio Asia-Taiwan in 2024. We are always pleased to meet up and converse with our existing business partners, new clients and everyone who wants to exchange ideas about nutraceutical products and the trends in the industry.

Following last year's motto, Bio Asia-Taiwan 2024 ran under the theme "Global View, Asian Touch", doubling down on the growing importance of the Taiwanese biomedical industries in a fast-moving region and the deepening cooperation with the regional and international community. With a one-day delay caused by a passing typhoon, the venue finally opened its doors to hundreds of local and international exhibitors and countless visitors eager to converse about new trends and products.

In countless seminars featuring over 100 renowned speakers, the exhibition offered valuable insights into the local industry as well as the latest research findings and nutraceutical innovations from partnering countries like Australia, Japan, Thailand, Belgium, India, and Malaysia. With Taiwan at the core of the Asian ICT industry and the recent leaps in AI technology, one day of Bio Asia-Taiwan's Innovation Forum was fully dedicated to the transformative role of AI in the pharmaceutical industry and drug development. We at Champion are excited to see the potential utilized to its fullest extent and strive to remain informed about the most recent advancements.

We are very honored to have been given the opportunity to introduce LYSOVETA™ to the Taiwanese market. LYSOVETA™ is an improved ingredient based on krill oil and in essence an advancement of the fish oil and Omega-3 supplements, which enjoy great popularity in Taiwan. The successful launch would not have been possible without the extensive support of our partner Aker BioMarine and Dr. David Lawrence Silver. The esteemed Dr. Silver led a seminar on the latest scientific findings regarding the transportation and use of the essential fatty acids EPA and DHA. In a specific form called lysophosphatidylcholine (LPC) they are more effectively transported to the brain and eye. Until recently, LPC-bound EPA/DHA was not available, however LYSOVETA™ now offers new opportunities to unlock the potential of targeted delivery of EPA/DHA. 

We are thrilled to see its use in Taiwan and look forward to the innovative applications and look forward to see you at Bio Asia-Taiwan 2025.